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1. Introduction
The incidence and prevalence of cancer has been increasing in such as degree that it has be‐
come the second or third leading cause of death worldwide, depending on ethnicity or
country in question and is consequently a major public health, cancer is a leading cause of
death in many countries, accounting for 7.6 million deaths (around 13% of all deaths) in
2008. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1
million deaths in 2030. About 30% of cancer deaths are due to the five leading behavioral
and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical ac‐
tivity, tobacco use, alcohol use [1-8].
Cancer is a generic term for a large group of diseases that can affect any part of the body,
cancer cells are significantly influenced by the surrounding stromal tissues for the initiation,
proliferation, and distant colony formation. When a tumour successfully spreads to other
parts of the body and grows, invading and destroying other healthy tissues, this process is
referred to as metastasis, and the result is a serious condition that is very difficult to treat,
because the progression to metastases is the leading cause of death associated to cancer.
Metastatic cells in this process must interact with the endothelium in three stages of tumor
progression. In recent years, the interaction between these cell populations has been seen as
part of a complex microenvironment tumor-associated. Mantovani et al. have even postulat‐
ed that this tumor microenvironment inflammatory plays an important role in tumorigene‐
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sis and tumor progression [18]. Tumor and normal surrounding cells such as endothelial
cells, soluble factors derived from this two cell populations and extracellular matrix [9-12],
compose the tumor microenvironment.
There are other factors in the development of cancer such as genetic, environmental, as well
as the role of oxidative stress and free radicals in response to damage caused by chemicals,
radiation, cellular aging, ischemic lesions and cells immune system [13]. Substances such as
antioxidants can protect cells against free radical damage. The damage caused by free radi‐
cals can lead to cancer. Antioxidants interact with free radicals to stabilize them so that, be‐
ing able to avoid some of the damage that free radicals can cause. It is important to analyze
the role of antioxidants as an alternative that contributes to cancer treatment and to promote
their use and consumption in cancer prevention
2. Tumoral progression
Tumors often become more aggressive in their behavior in more aggressive and their char‐
acteristics, although the time course may be quite variable, this phenomenon has been
termed tumor progression by Foulds [15].
In the early stages of the tumor progression, there is a detachment of cancer cells from the
primary tumor, followed by tumor cell adhesion to endothelial cells of venules in the target
organs. After the extravasations occurs extracellular matrix invasion by tumor cells, these
cells of primary lesions enter the lymphatics or the bloodstream depending on their anatom‐
ical location. In the circulation, many tumor cells are eradicated by physical forces exerted
on them to pass through the microvasculature of secondary organs, and immunological
mechanisms of action of host defense. Furthermore, once inside the target tissue tumor cells
must find favorable conditions for survival and proliferation [16-18]. The biological charac‐
teristic that define tumor progression have been extensively described, although the under‐
lying mechanisms are still not completely defined, however there are two theories have
been proposed to explain how tumor cells invade secondary sites where metastasis occurs
are the following [18-20]. The first is similar to the inflammatory process by cell adhesion
and migration, while the second involves the aggregation of circulating tumor cells, and that
these cells blocked blood vessels. In this theory in which a cell stably adhered frequently
starts a homotypic aggregation, capturing other circulating tumor cells, followed by the for‐
mation of multicellular aggregates, these aggregates once grow and emerge from the pri‐
mary tumor site, is carried out which triggers tumor progression in metastasis, where it
requires a coordinated interaction of tumor cells and vascular endothelial cells, play a criti‐
cal role in most of the events that characterize tumor progression and metastasis [21-23], so
it is important to mention the general aspects of endothelial biology:
2.1. Endothelial Biology
The endothelium is the thin layer of cells that lines the interior surface of blood vessels and
lymphatic vessels, forming an interface between circulating blood or lymph in the lumen
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and the rest of the vessel wall. The cells that form the endothelium are called endothelial
cells, these cells have very distinct and unique functions that are paramount to vascular biol‐
ogy. These functions include fluid filtration, formation of new blood vessels in the angiogen‐
esis, neutrophil recruitment. The endothelium acts as a semi-selective barrier between the
vessel lumen and surrounding tissue, controlling the passage of materials and the transit of
white blood cells, hormones into and out of the bloodstream. Excessive or prolonged in‐
creases in permeability of the endothelial monolayer, as in cases of chronic inflammation,
may lead to tissue edema. It is also important in controlling blood pressure, blood coagula‐
tion, vascular tone, degradation of lipoproteins an in the secretion of growth factors and cy‐
tokines [24-25]. In recent decades, it has become clear that the endothelium of venules and
smaller capillaries, and lymphatic vessels play a central role in the process of tumor growth,
dissemination of metastatic cells, which is accompanied by the development of a characteris‐
tic tumor vasculature and tumors formed by endothelial cells [26].
There are two phenotypes endothelial (constitutive and activated);
2.1.1. The constitutive phenotype of endothelial cells
Quiescent, resting endothelial cells in the adult form a highly heterogeneous cell population
that varies not only in different organs but also in different vessel calibers within an organ.
Endothelium in the normal adult male, although being metabolically active, considered qui‐
escent because the turnover of these cells is very low and this called: constitutive phenotype
Fig (1).
In this condition, the apical membrane of endothelial cells exhibits a very low amount of in‐
tercellular adhesion molecules, so that no adhesion of cellular blood components to the ves‐
sel walls [27].
2.1.2. The activated phenotype of endothelial cells
Endothelial cell activation is associated with a number of distinct phenotype changes that,
much like differentiation processes of the constitutive phenotype of endothelial cells, serve
their need to adapt to functional requirements. [28] The cytokine-induced phenotype of en‐
dothelial cells during inflammation has been characterized most extensively in the last few
years. When endothelial cells are activated by these cytokines are functional disorders in‐
volving immediate responses, for example, some pathological conditions such as sepsis, are
associated with endothelial conversion to a phenotype activated [29-30]. The activated phe‐
notype characterized by activation of constitutive nitric oxide synthase (NOS), also accom‐
panied by changes such as increased expression of cell adhesion molecules (CAMs) and E-
selectin (CD62E), ICAM-1(CD54), VCAM-1(CD106), P-selectin (CD62P) Fig (1). These
changes allow the endothelium to participate in pathological conditions including inflam‐
mation, coagulation, cell proliferation, metastasis, tumor angiogenesis. All these cellular in‐
teractions are regulated by temporal and spatial presentation of various cell adhesion
molecules and chemotactical molecules displaying appropriate specificity and affinity for
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proper development and functioning of the organism [31-32]. Has been postulated that this
phenotype or variants of it, are involved in the processes of metastasis [33].
Figure 1. There are two phenotypes endothelial constitutive and activated.
2.2. Metastasis
Metastasis is the result of cancer cell adaptation to a tissue microenvironment at a distance
from the primary tumor, is a complex process involving multiple steps: first, when cancer
cells break away from the primary tumor, they invade the host stroma, intravasate into lym‐
phatic or blood vessels, spread to the capillary bed of distant organs, where they invade into
new surrounding tissues and proliferate to form secondary tumors [34-35]. When cancer is
detected at an early stage, before it has spread, it can often be treated successfully by con‐
ventional cancer therapies such as surgery, chemotherapy, local irradiation, metastatic diffu‐
sion of cancer cells remains the most important clinical problem, because when cancer is
detected after known to have metastasized, treatment are much less successful [36]. The
metastatic capacity of tumor cells correlates with their ability to exit from the blood circula‐
tion, to colonize distant organs, and to grow in distant organs. Metastasis is a complex proc‐
ess that includes local infiltration of tumor cells into the adjacent tissue, transendothelial
migration of cancer cells into vessels known as intravasation, survival in the circulatory sys‐
tem, extravasation and subsequent proliferation in competent organs leading to colonization
[36-38]. Initially, tumor cell aggregates detachment from the primary tumor, next the cells
actively infiltrate the surrounding stroma and enter into the circulatory system, traveling to
distinct sites to establish the secondary tumor growth. In the bloodstream, a very small
number of tumor cells survive to reach the target organ, indicating that metastasis formation
must be regarded as a very ineffective event. Millions of carcinoma cells enter into the circu‐
latory system, but the majority of them die during transportation, and only 1-5% of viable
cells are successful in formation of secondary deposits in distinct sites [37-40]. Fig (2).
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Figure 2. Steps in the Metastasis process.
Metastasis is facilitated by cell-cell interactions between tumor cells and the endothelium in
distant tissues and determines the spread. Metastatic cells must act with the endothelium in
three different stages of tumor progression: initially during the formation of blood vessels that
enable tumor growth (vascularization), during the migration process that allows the pas‐
sage from tissue into the bloodstream (intravasation), and finally during the process allow‐
ing extravasation into the target tissue [41-43]. Metastatic cancer cells require properties that
allow them not only to adapt to a foreign microenvironment but also to subvert it in a way
that is conducive to their continued proliferation and survival [36-38]. In addition, direct tumor
cell  interactions  with  platelets,  fibroblasts  and  monocytes/macrophages,  polymorphonu‐
clear cells, soluble components, cytokines, chemokines, proteins of the extracellular matrix,
growth factors, and other molecules secreted by host cells, significantly contribute to cancer
cell adhesion, extravasation, and the establishment of metastatic lesions [44-47].
2.3. Cellular interactions in the inflammatory reaction and spread tumor
In the early stages of inflammation, neutrophils are cells that migrate to the site of inflam‐
mation under the influence of growth factors, cytokines and chemokines, which are pro‐
duced by macrophages and mast cells residing in the tissue [48]. The process of cell
extravasation from the bloodstream can be divided into four stages:
1. bearing
2. activation by stimulation chemoattractant
3. adherence
4. transendothelial migration.
If the inflammatory response is not regulated, the cellular response will become chronic and
will be dominated by lymphocytes, plasma cells, macrophages metastasis, which is favored
by the microenvironment of the organ target. The installation of tumor cells in blood vessels
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of the organ target to invade, is related to phenotypic changes in the endothelium allowing
vascular extravasation of blood circulation of leukocytes in the inflammatory reaction and, as
hypothesized current of tumor cells with metastatic capacity. The phenomenon of extravasa‐
tion in response to a tumor cell interaction cell endothelial or not allowing the passage of cells
whether there are appropriate conditions for the invasion with varied morphology [53-55].
Within the process of inflammation, a phenomenon is well-studied cell migration, which is
the entrance of polymorphonuclear neutrophils and the vascular system. This involves a se‐
quential mechanism of recognition, contact formation, and migration mediated by adhesion
molecules such as (ICAM-1, VCAM-1, E and P Selectins, Integrins) it has been demonstrated
that some of these adhesion molecules, such as E-selectin are not only involved in inflamma‐
tion, but also in tumor metastasis and play a significant role in cancer progression and meta‐
stasis, in some cases of colon cancer. [56-58]. The expression of ICAM-1 has also proven to
be a marker associated with an invasive phenotype [59].
Hanahanan et al. suggest that diversity of cancer cell genotypes is a manifestation of six ba‐
sics alterations in cell physiology that together indicate development of malignant growth
Fig (3), these alterations are shared in common by most all types of tumors [19]. In recent
years, it has been demonstrated that metastatic dissemination can be influenced by inflam‐
matory-reparative processes [46]. The interaction between these cell populations has been
seen as part of a complex inflammatory microenvironment tumor-associated. Mantovani et
al. have even postulated that this tumor microenvironment inflammatory plays an impor‐
tant role in tumorigenesis and tumor progression [60].
Figure 3. Capabilities of cancer and inflammation [19,60].
2.4. Inflammatory Microenvironment
The tumor microenvironment is composed of stromal fibroblasts, myofibroblasts, myoepi‐
thelial cells, macrophages, endothelial cells, leucocytes, and extracellular matrix (ECM) and
soluble factors derived from tumor cells. This inflammatory environment surrounding a tu‐
mor promotes the breaking of the basal membrane, a process required for the invasion and
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migration of metastatic cells [60]. Tumor cells are also capable of produce cytokines and che‐
mokines that facilitate evasion of the system immune and help to establishment and devel‐
opment of metastasis (Fig. 4). The increase of tumor-associated macrophages (TAMs) is
associated with poor prognosis through various mechanisms: a) release by macrophage
IL-10 and prostaglandin E2 which suppress antitumor response, b) easy to release angiogen‐
ic factors as VEGF, EGF, endothelin-2 and plasminogen activator promote tumor growth, c)
to facilitate cell invasion metastasis by releasing matrix metalloproteinases and induce TNF
production and vasodilatation enzyme nitric oxide synthase [61-62].
Figure 4. The tumor microenvironment and its role in promoting tumor growth
Cells grow within defined environmental sites and are subject to microenvironmental con‐
trol. Outside of their sites, normal cells lack appropriate survival signals. During tumor de‐
velopment and progression, malignant cells escape the local tissue control and escape death.
Diverse chemoattractant factors promote the recruitment and infiltration of these cells to the
tumor microenvironment where they suppress the antitumor immunity or promote tumor
angiogenesis and vasculogenesis.
TNF is expressed in low amounts by other cells such as fibroblasts, smooth muscle cells
and tumor cells, his target cell are primary endothelial cells, inducing their activation by
changing expression levels of some membrane proteins, primarily as adhesion molecules
E-selectin,  ICAM-1  and VCAM-1  whose  expression  and synthesis,  are  regulated  by  the
transcription factor kB nuclear. Activated endothelial phenotype induced by TNF and char‐
acteristics of the inflammatory response, have served to comparing the endothelial pheno‐
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type  has  been  observed,  is  produced in  response  to  contact  with  soluble  tumor  factors
[63-64].
The nuclear factor kappa B (NF-kB) is a transcription factor paramount in regulation of in‐
flammatory response genes Early involved in cell-cell interaction, communication intercellu‐
lar recruitment or transmigration, amplification of signals pathogenic and acceleration of
tumorigenesis [52-53,65].
The study of tumor cells to modify their microenvironment has been a growing area of in‐
terest, which has identified the secretion of pro-inflammatory cytokines such as TNF, IL-6)
and chemokines such as IL-8, it is interesting to note that these products are known modula‐
tors of endothelial function [53].
In recent years, it has been found that tumor cells secrete soluble factors, which modify the
endothelial constitutive phenotype, and that exposure to these factors increase to a greater
or less extent the capacity to adhere endothelial human tumor cells. It has been recognized
that these soluble factors released by tumor cells or non-tumor cells surrounding the tumor
play an important role in tumor progression [66].
Our group has shown that breast cancer cells, lymphomas, with high metastatic potentially
induces a change in human endothelial cells (HUVECs) that is characterized by promoting a
pro-adhesive endothelial phenotype, the expression of intercellular adhesion molecules
(ICAM-1, VCAM-1 and E-Selectin) and the activation of NF-kB [66]. These studies include
soluble factor leukemias (EUHE, Eusebia), cervical cancer (HeLa) and mammary gland can‐
cer (MCF-7, ZR), oral cancer. In all cases, we have used primary cultures of human endothe‐
lial cells (HUVECs), which have generated an in vitro model to study the tumor
microenvironment. This model is based on induction of a pro-adhesive endothelial pheno‐
type that is associated with expression of adhesion molecules E-selectin, ICAM-1, VCAM
dependent activation of NF-kB. These effects are considered essential in the process of adhe‐
sion and extravasation during the inflammatory reaction.
Moreover, we have analyzed the biochemical composition of the soluble factors derived
from tumor cells. Proteins such as 27, cytokines, chemokines and growth factors associated
with the inflammatory reaction; (IL-1 ra, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10,
IL-12, IL-13, IL-15, IL-16, TNF, IFN-gamma, IP-10,RANTES), (IL-8, Eotaxina, MCP-1, MIP-1
beta, MIP-1 alpha), (G-CSF, GM-CSF, PDGF, FGF, VEGF). The molecules identified most sig‐
nificant expression in breast carcinomas, were (VEGF, GM-CSF, IL-1ra, IL6, IL8, IP10,
RANTES), which play an important role in endothelial cell activation [52-53,65-66].
VEGF:
An unexpected finding was the abundant presence of the expression of vascular endothelial
growth factor (VEGF) in breast carcinoma lines. Whereas in normal cells the expression of VEGF
is dependent on a condition of hypoxia, surprisingly VEGF production by tumor cell lines and
occurred at a concentration of oxygen partial indicating 20% indicative of impaired VEGF
expression. In cancer constitutive secretion of VEGF independent of a condition that favors
hypoxic tumor angiogenesis and growth in a clinical setting and is a marker of poor prognosis
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[67]. In cancer, constitutive secretion of VEGF-independent hypoxic condition favors tumor
angiogenesis and growth in a clinical setting and is a marker of poor prognosis [68].
GM-CSF
The involvement of GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) in can‐
cer is complex, since it seems to require the presence of other cytokines such as IL-4 and
IL-6, and there are reports antagonistic to their involvement in tumorigenesis. For example,
expression of GM-CSF and interleukin-12, inhibits the immune response and being ex‐
pressed on B16 murine melanoma cells, decreasing completely tumorigenic capacity of syn‐
genic mice C57B/6. In contrast to the line described breast epithelial MCF7-A benign growth
factors secreted able to induce expression of IL-6 and GM-CSF in the tumor line R2T1AS
breast cancer that is associated with a higher rate of growth and a higher tumorigenic ca‐
pacity in vivo. Moreover, continued exposure of GM-CSF plus IL-4 of mesenchymal cells
from human bone marrow, resulted in an increase in the morphological transformation and
increased rate of growth both in vitro and in vitro mesenchymal cells, indicating the induc‐
tion of a transformed phenotype. Whereas previous reports indicate that the involvement of
GM-CSF requires other cytokines [69-70].
IL-1ra
It is reported that the soluble form of IL-1 receptor could serve as a functional antagonist of
IL-1, the presence of this protein is controversial, since IL-1 by trapping an anti-inflammato‐
ry effect would reduce the adhesion of cells added by tumor cells and their extravasation,
given this scenario could be proposed that tumor cells not only produce pro-inflammatory
factors through the release of soluble factors tumor, but it can regulate the inflammatory
process [71].
IL-6
The IL-6 is recognized as a classic inducer of the states of chronic inflammation and that pro‐
mote the activation of vascular endothelium. It has also been reported that IL-6 is produced
by tumors that develop metastases to the liver, as the case of colon and mammary gland
cancer. The activity of this cytokine in the soluble factors tumor could be further enhanced
by the presence of other co-factors secreted by cells [72-73].
IL-8
Expression of IL-8 in colorectal cancer favors an increase in tumorigenesis and metastasis,
this increase is due to IL-8 is associated with expression of MMP-2 and MMP-9, the activity
of these metalloproteases have been identified in physiological tissue remodeling processes
like normal healing, but also participate in tissue remodeling associated with pathological
processes including invasion [74]. Also in melanomas have been identified as IL-8 acts as an
angiogenic factor and also promotes mitosis, therefore the IL-8 has been postulated as a po‐
tential therapeutic target. In particular, we have sought to interfere with IL-8 with the pur‐
pose of reducing tumor growth, an alternative that has developed is the use of an anti-IL-8
in nude mice with liver cancer. The results show that administration of neutralizing anti-IL8
significantly decreased tumor growth, even more interestingly this decrease is associated
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with decreased expression of MMP-2 and MMP-9. Something similar is observed using the
same experimental treatment of melanoma with a decrease in angiogenesis [75]. In our re‐
sults, we found increases in IL-8 in the soluble factors soluble breast cancer [66]. This indi‐
cates that IL-8 could be used as a marker associated with tumor progression, regardless of
tumor type. In patients where they identified the production of IL-8, using neutralizing anti‐
bodies that interfere with their signaling could serve as a therapeutic alternative.
IP10
IP10 is a protein induced by interferon, has been reported that this protein inhibits prolifera‐
tion and metastatic tumors, that expression of IP10 in patients with stages II and III colorec‐
tal cancer correlate with the development of metastasis and a poor prognosis. The detection
of IP10 could be used as a prognostic marker in stage II and III colorectal cancer patients.
This has led to propose that IP10 might be used as a prognostic marker in stage II and III
colorectal cancer patients [76-77].
RANTES
Regulated upon activation normal T-cell expressed, and secreted is a chemokine that be‐
longs to the CC class, which distinguishes it from IL8, which belongs to the CXC class.
RANTES expression in tumor cells has been associated with tumorigenesis and is consistent
with our finding of RANTES the products secreted by breast carcinomas. The presence of
RANTES in the tumor microenvironment may be chemoattractant to tumor cells. From this
point of view is interesting that the tumor-associated endothelial cells, when stimulated
with MIF1-alpha can release RANTES [78]. Study that evaluated the expression of RANTES
and its receptor CCR5 in 60 patients with metastatic gastric cancer, were identified elevated
expression levels, where it is concluded that RANTES and its receptor may contribute to
gastric cancer metastasis by promoting responses TH1 and TH2. By comparing a variety of
biological markers in a group of biopsies of mammary gland cancer, RANTES was the only
marker present in all biopsies [79].
The reported findings strengthen the idea that soluble factors of tumor microenvironment
may be relevant in the final stages of the metastatic spread and that these effects may be
mediated by cytokines, chemokines, and growth factors present in the soluble factors secret‐
ed by tumor cell lines. These elements found in high concentrations are known to be capable
of inducing the activated phenotype of endothelial cells to a variety of physiological and
pathological cellular responses.
3. Oxidative stress and free radicals: role in cancer development
During the inflammatory process macrophages and endothelial cells, generate a large
amount of growth factors, cytokines and reactive oxygen species (ROS) and nitrogen (RNS)
that can cause DNA damage. If macrophages and remain on the endothelium may allow the
tissue damage continues chronic inflammation predisposes to malignancy [56,80].
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3.1. Introduction
In different pathological process the cell injury is induced by free radicals, is an important
mechanism of cell damage in many pathological conditions, such as chemical and radiation
injury, ischemia injury, cellular aging and some immune system cells such as the phagocytes
[82-84]. The free radicals are an example of instability in a biological system; namely, are
chemical substances that they have an unpaired electron in its final orbit, this causes that
their energy to be unstable and for they become stable they need for molecules which are
adjacent to it either organic or inorganic for example: lipids, proteins, carbohydrates and nu‐
cleic acids essentials compounds in the cells mainly in the membrane and the core.
These types of chemical species may be either.
1. Oxygen derived (reactive oxygen species ROS)
2. Nitrogen derived (reactive nitrogen species RNS)
Reactive oxygen species (ROS) and reactive nitrogen (RNS) (Table 1) are created in the some
cells such as the hepatocytes and in different normal physiologic processes, including, oxi‐
dative respiration, growth, regeneration, apoptosis and microbial killing by phagocytes [83].
The generation of this species chemical types, is normal in a normal cells; however, when
these start to produce in excess and the antioxidant system is deficient, oxidative stress oc‐
curs. This causes damage cells: hepatocytes, kupffer cells and endothelial cells, through in‐
duction of inflammation, ischemia, fibrosis, apoptosis, necrosis or other atypical
transformation in the cell structure and function.
Type of radical Activating enzyme Physiological process
Nitrogen derived
(nitric oxide)
Oxygen derived
(ROS)
Nitric oxide synthase
NADPH oxidase
Smooth muscle (control or vascular tone) and other
cGMP- depended functions. (glycogenolysis, apoptosis,
conductance regulator ion channels, vasodilatation
and increased blood flow)
Oxidation-reduction reactions within the cell, muscle
relaxation, control of erythropoietin production, signal
transduction from various receptors, enhancement of
immunological functions and oxidative
Table 1. Important physiological process involved with the free radicals.ROS, Reactive oxygen species.
3.2. Reactive oxygen species
Reactive oxygen species are produced in normal condition them in a living cell during cellu‐
lar respiration, energy production and various events of growth and cell death, these are de‐
grade by the defensive systems. Therefore, the cells self-regulate their production and
degradation of ROS is found transiently in the cell without causing any damage to the cellu‐
lar level, and for that reason the cell maintains an equilibrium constant but as this produc‐
tion increases oxidative stress is generated, this relates whit different pathological process
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such as damage in the cell structure and function, degenerative process and cancer, also in‐
fluence within the inflammation and the immune response, as these are generated by macro‐
phages and neutrophils as mediators for the destruction of pathogens and dead tissue. The
generation of free radicals can be made by different pathways [85-86]. (Table 2)
Redox reactions in metabolic processes. During cellular respiration O2 is reduced by four
electrons to the transport of H2 for generating two
molecules of water through an oxidative enzyme
which results is the formation of superoxide anion
(electron), hydrogen peroxide (two electron ) and
hydroxyl ions (three electrons).
Absorption of radiant energy Electromagnetic radiation (x rays), gamma rays,
infrared, UV, microwave etc. These to hydrolyze the
water and generate hydroxyl ions and hydrogen
Inflammation and immune response. This response induced by activated leukocytes, that
is caused by a protein complex located at the
plasma membrane that employs NADPH oxidase
and some intracellular oxidase and this generated a
superoxide anion.
Metabolism of drugs Most chemicals do not show biological activity in its
native form these have to become toxic reactive
metabolites to act on their target molecules. This is
made by oxidases. These metabolites induce the
formation of free radicals, such as acetaminophen.
Metals The transmission metals donate or accept electrons
intracellular free during the reactions thus causing
the formation of free radicals
Nitric oxide Nitric oxide is generated by different cells are an
example of this are the endothelial cells giving rise
to reactive species of nitrogen, such as the
peroxynitrite anion (ONOO-) also NO2 and NO3 -.
Table 2. The generation of free radicals can be made by different pathways.
3.3. Free radical and carcinogenesis
Free radicals are atoms or groups of atoms that in their atomic structure present one or more
unpaired electrons in the outer orbit. These free radicals steal electrons from other molecules
in effort to heal themselves, ultimately creating new free radicals in the process by stealing
electrons. Free radicals are formed from a number of causes such as cigarette smoke, pollu‐
tion, exposure to sunlight all cause the formation of free radicals. Other factors include nor‐
mal daily processes like food digestion and breathing.
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When increased production of reactive species and have a deficiency in the antioxidant sys‐
tem they cause significant neoplastic changes. In some diseases, such as Bloom syndrome
develops lymphomas, leukemias and carcinomas, in anemia are implicated the production
of these and alterations of antioxidant defense mechanisms at the systemic level [82-83].
Some epidemiological information indicates that tumor incidence is lower in populations
where the diet is rich in antioxidants like fruits and vegetables [84].
Tumor cells have a high activity of free radical formation in contrast to healthy cells. It is
known that tumor cells not only produce oxygen peroxide (H2O2) but also decreases the pro‐
duction of antioxidants such as glutathione peroxidase and SOD.
Some pathways by which cancer cells have high amounts of ROS is for multiple factors:
Increasing the metabolic activity of a neoplastic cell, lead to the increased energy require‐
ments (ATP) produced in the mitochondria this in order to enhance the growth and prolifer‐
ation.
1. The progression of cancer, primarily because of the damage they cause in to the genetic
material of a normal cell. Has been shown that the oxidation of guanine to 8-oxo-dG
(oxidation product DNA) induces errors in their replication. By dependent of DNA pol‐
ymerase that generates the nitrogenous base pairing, not complementary, to permit the
establishment of hydrogen bonds with (A) adenine and (T) thymine [85].
2. Oncogenic transformation is conditioned by the presence of mutated genes or onco‐
genes that control essential cellular functions in which the redox state within or outside
the cellular microenvironment is very important ROS are potential carcinogens because
they facilitate mutagenesis, tumor growth, and metastasis and all those process that has
been showed [86].
Cancer is a multifactorial disease where endogenous and exogenous factors are involved but
the roles played by free radicals in this disease are very important because, these produce
damage in de DNA structure and this produces an important negative effects [86].
4. Antioxidants and Chemoprevention in cancer
Antioxidants are substances that prevent damage to cells caused by free radicals, it can
cause damage to DNA, leading to the possible development of cancer [87]. Antioxidants
search for these free radicals and lend them an, this stabilizes the molecule, thus preventing
damage to other cells. Antioxidants also turn free radicals into waste by products, and they
eventually are eliminated from the body. The inability of our body to neutralize free radicals
we are exposed daily forces us to rely on foods with antioxidant properties capable of neu‐
tralizing them [88].
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4.1. Flavonoids
Flavonoids are found in numerous plants and vegetables, with a wide distribution through
the plant kingdom. This class compounds numbers more than 4000 members and can be
divided into five subcategories: flavones, monomeric flavanols, flavanones, flavonols and
anthocyanidines. Are natural compounds chemically derivate from bezo-y-pirone (phenyl‐
chromone) or flavone. They are considered important constituents of the human diet. It has
been reported that they exert multiple biological effects due to their antioxidant and free
radical-scavenging abilities [89].
Flavanoids possess a lot of pharmacological and therapeutically properties; antioxidant, an‐
titumor, antiangiogenic (vascular protective), anti-inflammatory, antiallergic, antihepatotox‐
ic, anticancerigenic, antimutagenic, anticancer effects, antiosteoporotic, and antiviral
properties [90]. Many studies emphasize take adequate diets that are active allies against
cancer. These diets are based on enzymes and antioxidant substances in certain foods that
are rich in components that collect above [91].
They also have the ability to repair previous damage to cells, examples of antioxidants in‐
clude (beta-carotene, lycopene, vitamins C, E, and A), and other substances. Nutrients such
as; green tea, flavonoids, vitamins C, E, and Beta-carotene in the carcinogen process, has
been showed that have function in the elimination of carcinogenic factors, inhibition of pre-
carcinogens and reparation of DNA damage. The mechanisms are diverse and range from
inhibition to an active reaction of the immune system in general. This has caused the use of
multiple antioxidant micronutrients as preventive agents [90]. Several experimental data
have demonstrated the antiproliferative and anti-carcinogenic and the role of chemopreven‐
tive agent of flavonoids [91-92].
Currently investigations are performed to determine the mechanisms by which act flavo‐
noids, because it has been observed that their effects are greater at high doses, which gives
them inducing  side  effects,  so  it  is  important  to  moderate  their  consumption  by  a  bal‐
anced diet.
5. Conclusions
It is important to analyze the role of tumor-associated inflammatory microenvironment and
has been identified that plays an important role in tumor progression. This microenviron‐
ment is composed of molecules that play an important role in inflammatory processes and
chronic, and favor the invasion and metastasis process that triggers the death of many peo‐
ple with any cancer.
The installation of tumor cells in blood vessels of the target organ to invade, is related to
phenotypic changes in the endothelium allowing vascular extravasation of blood circulation
of leukocytes in the inflammatory reaction and, as hypothesized current of tumor cells with
metastatic capacity. The phenomenon of extravasation in response to a cell interactions be‐
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tween tumor cells and endothelial cells or not allowing the passage of cells whether there
are appropriate conditions for the invasion.
Understanding the molecular basis of these interactions between metastatic cells and endo‐
thelial cells, will enable us to design strategies to interfere with this inter-cellular communi‐
cation. It is important to recognize the tumor-associated inflammatory microenvironment
and what is the contribution to tumor progression. The importance of these factors on endo‐
thelial activation being evaluated by reconstituting the mixture with cytokines, chemokines
and growth factors recombinant depleted mixtures of tumor soluble factors of each of these
proteins by specific monoclonal antibodies.
Is important mention that during the inflammatory process macrophages, fibroblasts and
endothelial cells generate a large amount of growth factors, cytokines, chemokines and reac‐
tive oxygen species (ROS) and nitrogen (RNS) that can cause DNA damage. These process
allow the tissue damage continues chronic inflammation predisposes to malignancy. There‐
fore, it is important to note that people with chronic degenerative diseases, which clearly
show chronic inflammatory processes, they may promote or contribute to present or devel‐
op a tumor lesion.
The use of antioxidants consumed in a balanced diet can be used as an element in the diet
that can become a preventive or contributing to diminish the appearance of a tumor lesion.
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